8-KLeadership ChangesExhibits & Filings

Medtronic plc 8-K Report, Executive Changes (Jun 26, 2023)

Filed June 26, 2023For Securities:MDT

Summary

Medtronic plc (MDT) announced a change to its Board of Directors, appointing Greg Lewis as a new director effective June 26, 2023. This appointment increases the size of the Board from 11 to 12 members. Mr. Lewis will also serve on the Audit committee and the Finance and Financial Risk committee, bringing his expertise to key oversight functions of the company. Investors should note that Mr. Lewis's appointment is part of the company's standard director compensation policy, and he will receive an annual cash retainer and an equity grant. The filing confirms there are no disqualifying arrangements or reportable transactions between Mr. Lewis and Medtronic. This is a routine governance update, but the addition of a director to specialized committees is a notable development for board oversight.

Key Highlights

  • 1Medtronic plc appointed Greg Lewis as a new director to its Board of Directors.
  • 2The size of the Board of Directors has been increased from 11 to 12 members.
  • 3The appointment of Greg Lewis is effective as of June 26, 2023.
  • 4Mr. Lewis has been appointed to serve on the Audit committee.
  • 5Mr. Lewis has also been appointed to serve on the Finance and Financial Risk committee.
  • 6Mr. Lewis will receive compensation in accordance with Medtronic's non-employee director compensation policy, including an annual cash retainer and a director equity grant.
  • 7There are no disclosed related-party transactions or disqualifying arrangements concerning Mr. Lewis's appointment.

Frequently Asked Questions

Greg Lewis has been appointed as a new director to Medtronic's Board. The filing does not provide specific details about Mr. Lewis's background or the exact reasons for his appointment, other than it increases the Board size and he will serve on key committees. Information regarding his qualifications and any prior relationship with Medtronic is typically found in the company's proxy statements or subsequent disclosures.

Mr. Lewis's appointment to these committees suggests the Board values his expertise in financial oversight and risk management. The Audit Committee plays a crucial role in overseeing financial reporting and internal controls, while the Finance and Financial Risk committee likely focuses on the company's financial strategy and management of financial risks. His presence could bring fresh perspectives to these critical areas.

This 8-K filing is primarily a governance update concerning the Board of Directors. While new directors can influence strategy over time through their participation in Board decisions, this specific announcement does not directly detail any immediate impact on Medtronic's financial performance or operational strategy. The focus is on the composition and oversight capabilities of the Board.

The filing states that Mr. Lewis will be eligible to receive an annual cash retainer and a director equity grant as described under 'Corporate Governance—Director Compensation' in Medtronic's Definitive Proxy Statement on Schedule 14A filed on August 19, 2022. Investors can refer to that document for details on the company's standard director compensation practices.